Virulence factor expression by Gram-positive cocci exposed to subinhibitory concentrations of linezolid.
Linezolid is a new oxazolidinone with potent antibacterial activity against Gram-positive cocci; it uniquely inhibits bacterial translation through inhibition of 70S initiation complex formation. The effects of sub-growth-inhibitory concentrations of linezolid on the expression of various structural and soluble virulence factors of Staphylococcus aureus and Streptococcus pyogenes were examined. For S. aureus, strains Wood 46 and Cowan 1 (NCTC 8532) were used to measure protein A, coagulase, alpha-haemolysin (hla) and delta-haemolysin (hld). For S. pyogenes, strain NCTC 9994 was used to measure M protein, streptolysin O (SLO) and DNase. Coagulase was assayed by clotting of citrated rabbit plasma, and hla, hld and SLO by lysis of rabbit, human and horse erythrocytes, respectively. Protein A and M protein were measured indirectly using bacterial susceptibility to phagocytic ingestion of radiolabelled bacteria by human neutrophils. When S. aureus was grown in 1/2, 1/4 and 1/8 MIC, linezolid, coagulase, hla and hld production were impaired. Susceptibility to phagocytosis was changed by growth in the presence of 1/2 MIC linezolid compared with that in its absence (50.8 +/- 4.1% versus 38.9 +/- 2.9%; P <or= 0.05). When S. pyogenes was grown in 1/2, 1/4 and 1/8 MIC linezolid, SLO and DNase production were impaired compared with that of bacteria grown in the absence of the drug; its susceptibility to phagocytosis was also increased (52.8% bacteria ingested versus 37.5%; P <or= 0.05). A reduction in virulence factor expression at sub-MIC linezolid concentrations may be of benefit in the treatment of Gram-positive infections.
Gemmell
Curtis G
CG
University Department of Bacteriology and Immunology, University of Glasgow, Royal Infirmary, 84-86 Castle Street, Glasgow G4 OSF, UK. cgglg@clinmed.gla.ac.uk
Ford
Charles W
CW
D000081:Acetamides / Q000008:administration & dosage*; D006095:Gram-Positive Cocci / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D000069349:Linezolid; D023303:Oxazolidinones / Q000008:administration & dosage*; D010586:Phagocytes / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000378:metabolism; D013297:Streptococcus pyogenes / Q000187:drug effects / Q000378:metabolism; D037521:Virulence Factors / Q000096:biosynthesis*
D000081:Acetamides; D023303:Oxazolidinones; D037521:Virulence Factors; D000069349:Linezolid